Small Company Offering and Sale of Securities Without Registration (d)
May 27 2020 - 3:14PM
Edgar (US Regulatory)
o
NoneEntity Type | 0001642178 | Breathtec BioMedical, Inc. Breathtec Biomedical, Inc. |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
Name of Issuer |
Algernon Pharmaceuticals Inc. |
Jurisdiction of Incorporation/Organization |
BRITISH COLUMBIA, CANADA |
|
Year of Incorporation/Organization |
|
o
| Over Five Years Ago |
|
x
| Within Last Five Years (Specify Year) | 2015 |
|
o
| Yet to Be Formed | |
2. Principal Place of Business and Contact Information |
Name of Issuer | |
Algernon Pharmaceuticals Inc. | |
Street Address 1 | Street Address 2 |
SUITE 915 - 700 WEST PENDER STREET | |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
VANCOUVER | BRITISH COLUMBIA, CANADA | V6C 1G8 | 604-646-1553 |
Last Name | First Name | Middle Name |
Moreau | Christopher | |
Street Address 1 | Street Address 2 |
Suite 915 - 700 West Pender Street | |
City | State/Province/Country | ZIP/Postal Code |
Vancouver | BRITISH COLUMBIA, CANADA | V6C 1G8 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Sadhra | Michael | |
Street Address 1 | Street Address 2 |
Suite 915 - 700 West Pender Street | |
City | State/Province/Country | ZIP/Postal Code |
Vancouver | BRITISH COLUMBIA, CANADA | V6C 1G8 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Attariwala | Raj | |
Street Address 1 | Street Address 2 |
Suite 915 - 700 West Pender Street | |
City | State/Province/Country | ZIP/Postal Code |
Vancouver | BRITISH COLUMBIA, CANADA | V6C 1G8 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Levine | David | |
Street Address 1 | Street Address 2 |
Suite 915 - 700 West Pender Street | |
City | State/Province/Country | ZIP/Postal Code |
Vancouver | BRITISH COLUMBIA, CANADA | V6C 1G8 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
o
| Agriculture | | Health Care |
o
| Retailing |
| Banking & Financial Services | |
x
| Biotechnology |
o
| Restaurants |
|
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
|
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
|
o
| Investing | |
o
| Pharmaceuticals | |
o
| Telecommunications |
|
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
|
o
| Pooled Investment Fund
| | | | | Travel |
|
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| Real Estate | |
o
| Lodging & Conventions |
|
o
| Commercial | |
o
| Tourism & Travel Services |
|
o
| Construction | |
o
| Other Travel |
|
o
| REITS & Finance |
o
| Other |
|
o
| Residential | |
|
o
| Other Real Estate | |
o
| Business Services | |
| Energy | |
|
o
| Coal Mining | |
|
o
| Electric Utilities | |
|
o
| Energy Conservation | |
|
o
| Environmental Services | |
|
o
| Oil & Gas | |
|
o
| Other Energy | |
Revenue Range | Aggregate Net Asset Value Range |
o
| No Revenues |
o
| No Aggregate Net Asset Value |
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
o
| Over $100,000,000 |
o
| Over $100,000,000 |
x
| Decline to Disclose |
o
| Decline to Disclose |
o
| Not Applicable |
o
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
|
o
| Investment Company Act Section 3(c) |
x
| New Notice | Date of First Sale | 2020-05-13 |
o
| First Sale Yet to Occur |
Does the Issuer intend this offering to last more than one year? |
x
| Yes |
o
| No |
9. Type(s) of Securities Offered (select all that apply) |
o
| Pooled Investment Fund Interests |
x
| Equity |
o
| Tenant-in-Common Securities |
o
| Debt |
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
x
| Other (describe) |
| Each Special Warrant is convertible into a unit comprised of a share and one
warrant for no additional consideration. Each warrant is exercisable into a
share at C$0.55 per share for 24 months, subject to acceleration. |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
|
Clarification of Response (if Necessary) | |
|
Minimum investment accepted from any outside investor | $ 0 USD |
Recipient | Recipient CRD Number |
o
| None |
| |
(Associated) Broker or Dealer |
o
| None | (Associated) Broker or Dealer CRD Number |
o
| None |
| |
Street Address 1 | Street Address 2 |
| |
City | State/Province/Country | ZIP/Postal Code |
| | |
State(s) of Solicitation |
o
| All States |
|
|
13. Offering and Sales Amounts |
Total Offering Amount | $ 128442 USD |
o
Indefinite |
Total Amount Sold | $ 49949 USD | |
Total Remaining to be Sold | $ 78493 USD |
o
Indefinite |
|
Clarification of Response (if Necessary) |
200835 Special Warrants at C$0.35(US$0.25) per Special Warrant, convertible into a share and a warrant, exercisable at C$0.55(US$0.39) for 24 months, subject to acceleration. No guarantee that Warrants will be exercised. Exchange rate of US$1:C$0.7106. |
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
| |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 1 |
15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 0 USD |
o
| Estimate |
Finders' Fees | $ 0 USD |
o
| Estimate |
|
Clarification of Response (if Necessary) |
|
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| $ 0 USD |
o
Algernon Pharmaceuticals (QB) (USOTC:AGNPF) Historical Stock Chart From Oct 2024 to Nov 2024
Algernon Pharmaceuticals (QB) (USOTC:AGNPF) Historical Stock Chart From Nov 2023 to Nov 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|